Article Text

Download PDFPDF

P146 Fracture risk in systemic lupus erythematosus patients over 25 years
  1. Sara Moreira Pinto1,
  2. Daniela Garelick2,
  3. Filipa Farinha3,
  4. Tatiana Pires4,
  5. Emon Khan3 and
  6. David Isenberg3
  1. 1Internal Medicine Dept., Pedro Hispano Hospital, Porto, Portugal
  2. 2Rheumatology Dept., Sheba Medical Center, Ramat Gan, Israel
  3. 3Rheumatology Dept., University College London Hospital, London, UK


Background Osteoporosis and fractures are complications of glucocorticoid treatment. Current EULAR guidelines for the treatment of SLE recommend minimising long term glucocorticoid aiming at ≤ 7.5 mg/day. We examined the relationship of glucocorticoid dosing on fracture risk in patients with SLE.

Methods Retrospective data collection on SLE patient attending University College London Hospital clinic over a 35year period. The data included consecutive steroid dosing, Bone marrow density scans (BMD) and fragility fractures.

Results We reviewed 250 patients selected because we had a minimum of 10yrs follow up on them, 229 female (92%), 130 Caucasian (52%), 62 (25%) Afro-Caribbean and 45 (18%) South Asian. Mean age of SLE diagnosis was 27years and 27% were smokers. Fragility fractures were diagnosed in 28 patients (11%), mean age of the first fracture 51 years ± 16 years. Ten patients (36%) were diagnosed with osteoporosis prior to the fracture (p 0.006). The majority, 94% of patients were treated with glucocorticoids with an average daily dosing of 6.20 mg/day. Patients with fractures, had a lower average daily dosing – 5.36 mg/day (p 0.127), but had a higher median cumulative dose (25.19 g versus 20.96 g, p 0.229). The majority of patients received vitamin D and calcium supplementation (92% p 0.109 and 84% p 0.163 respectively). However, hyperparathyroidism (n =6) was significantly associated with fragility fractures (p value 0.020). The presence of end-chronic kidney disease or rheumatoid arthritis were not related to the development of fractures (p 0.381; p 0.139, respectively). Regarding treatment, 22 patients with fractures were treated with bisphosphonates (p <0.001), two had denosumab (p 0.034) and two had teriparatide (p 0.012).

Abstract P146 Table 1

Characteristics of the population studied and comparison between patients with and without fragility fractures

Conclusions In our cohort, there was no statistically significant association between glucocorticoids treatment and fragility fractures. Hyperparathyroidism was significantly correlated with fragility fractures in our group. The majority of patients averaged daily dosing in accordance with EULAR recommendations.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.